Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Prolonged Molecular and Clinical Remissions in Follicular Lymphoma Patients Treated with HDT/ASCT and Combination Immunotherapy with Rituximab and Interferon α

Liam Smyth, MD FRCPath, Rena Buckstein, MD FRCPC, Pennell Nancy, BSc, Rashmi Weerasinghe, Matthew Cheung, MD MS, FRCP, Eugenia Piliotis, MD FRCP, MD, Kevin Imrie, MD, David Spaner, MD PhD, Marciano D. Reis, MD, Lisa Chodirker, MD, Zeina Ghorab, Violet ruth,nancy Milliken, Angela Boudreau, RN, BScN, MN, CON(C), Neil Berinstein, MD

Blood (2017) 130 (Supplement 1): 4069.

https://doi.org/10.1182/blood.V130.Suppl_1.4069.4069

Published: 2017

Journal Articles

HBV Care Map for Patients Receiving Anti-CD20 Therapy

Zachary Liederman, MD, Neil Berinstein, MD, Michael Crump, MD, Jessica Hwang, MD MPH, Harry L.A. Janssen, PhD MD, C. Tom Kouroukis, MDMSc,FRCPC, Patricia Leung, Anna Lok, MD, Colina Yim, Andrew D. Zelenetz, MD PhD, Kelvin Chan, MD PhD, Jordan Feld, MD MPH, Lisa K. Hicks, MD MSc

Blood (2017) 130 (Supplement 1): 4697.

https://doi.org/10.1182/blood.V130.Suppl_1.4697.4697

Published: 2017

Journal Articles

Rituximab Based Regimen May Decrease the Incidence of CNS Relapse in Patients with Diffuse Large B-Cell Lymphoma.

Mervat Mahrous Mohamed, MD, Rena Buckstein, MD, FRCPC, Eugenia Piliotis, MD, Matthew C Cheung, MD, Neil Berinstein, MD

Blood (2009) 114 (22): 4770.

https://doi.org/10.1182/blood.V114.22.4770.4770

Published: 2009

Journal Articles

Hypogammaglobulinemia Following Rituximab and High-Dose Therapy and Autologous Stem-Cell Transplant: Incidence and Predictors of Prolonged Immunoglobulin Deficiencies

Nancy Pennell, Matthew Cheung, MD SM, FRCP, Lisa K Hicks, MD, MSc, Rena Buckstein, MD, FRCPC, Kevin R Imrie, MD, Eugenia Piliotis, MD, David Spaner, Zeina Ghorab, Marciano D. Reis, MD, Violet Milliken, Angela Boudreau, Neil Berinstein, MD

Blood (2008) 112 (11): 4351.

https://doi.org/10.1182/blood.V112.11.4351.4351

Published: 2008

Journal Articles

High Dose Therapy / ASCT with Rituximab for In-Vivo Purging and Post-ASCT Consolidation in Relapsed Follicular Lymphoma Achieves Prolonged Clinical and Molecular Remissions.

Anthony C. Woods, MD, Rena Buckstein, MD, Joy Mangel, MD, Kevin Imrie, MD, David Spaner, MD, Michael Crump, MD, Nancy Pennell, B.Sc, Angela Boudreau, M.Sc, Marciano Reis, MD, Neil Berinstein, MD

Blood (2004) 104 (11): 914.

https://doi.org/10.1182/blood.V104.11.914.914

Published: 2004

Journal Articles

A Simplified Real-Time PCR Method for the Quantification of Minimal Residual Disease in Follicular Lymphoma.

Nancy Pennell, M.Sc, Anthony Woods, MD, Rena Buckstein, MD, Kevin Imrie, MD, David Spaner, MD, Marciano Reis, MD, Neil Berinstein, MD

Blood (2004) 104 (11): 5203.

https://doi.org/10.1182/blood.V104.11.5203.5203

Published: 2004

NARROW

Prolonged Molecular and Clinical Remissions in Follicular Lymphoma Patients Treated with HDT/ASCT and Combination Immunotherapy with Rituximab and Interferon α

HBV Care Map for Patients Receiving Anti-CD20 Therapy

Rituximab Based Regimen May Decrease the Incidence of CNS Relapse in Patients with Diffuse Large B-Cell Lymphoma.

Hypogammaglobulinemia Following Rituximab and High-Dose Therapy and Autologous Stem-Cell Transplant: Incidence and Predictors of Prolonged Immunoglobulin Deficiencies

High Dose Therapy / ASCT with Rituximab for In-Vivo Purging and Post-ASCT Consolidation in Relapsed Follicular Lymphoma Achieves Prolonged Clinical and Molecular Remissions.

A Simplified Real-Time PCR Method for the Quantification of Minimal Residual Disease in Follicular Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Prolonged Molecular and Clinical Remissions in Follicular Lymphoma Patients Treated with HDT/ASCT and Combination Immunotherapy with Rituximab and Interferon α

HBV Care Map for Patients Receiving Anti-CD20 Therapy

Rituximab Based Regimen May Decrease the Incidence of CNS Relapse in Patients with Diffuse Large B-Cell Lymphoma.

Hypogammaglobulinemia Following Rituximab and High-Dose Therapy and Autologous Stem-Cell Transplant: Incidence and Predictors of Prolonged Immunoglobulin Deficiencies

High Dose Therapy / ASCT with Rituximab for In-Vivo Purging and Post-ASCT Consolidation in Relapsed Follicular Lymphoma Achieves Prolonged Clinical and Molecular Remissions.

A Simplified Real-Time PCR Method for the Quantification of Minimal Residual Disease in Follicular Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only